Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jöbsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA Jr. Badesch DB, et al. Ann Intern Med. 2000 Mar 21;132(6):425-34. doi: 10.7326/0003-4819-132-6-200003210-00002. Ann Intern Med. 2000. PMID: 10733441 Clinical Trial.
Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension.
Langleben D, Christman BW, Barst RJ, Dias VC, Galiè N, Higenbottam TW, Kneussl M, Korducki L, Naeije R, Riedel A, Simonneau G, Hirsch AM, Rich S, Robbins IM, Oudiz R, McGoon MD, Badesch DB, Levy RD, Mehta S, Seeger W, Solèr M. Langleben D, et al. Among authors: badesch db. Am Heart J. 2002 May;143(5):E4. doi: 10.1067/mhj.2002.121806. Am Heart J. 2002. PMID: 12040360 Clinical Trial.
Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension.
McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, Robbins IM, Tapson VF, McGoon MD, Badesch DB, Sigman J, Roscigno R, Blackburn SD, Arneson C, Rubin LJ, Rich S; Treprostinil Study Group. McLaughlin VV, et al. Among authors: badesch db. J Cardiovasc Pharmacol. 2003 Feb;41(2):293-9. doi: 10.1097/00005344-200302000-00019. J Cardiovasc Pharmacol. 2003. PMID: 12548091 Clinical Trial.
Beraprost therapy for pulmonary arterial hypertension.
Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, Flinchbaugh R, Sigman J, Arneson C, Jeffs R; Beraprost Study Group. Barst RJ, et al. J Am Coll Cardiol. 2003 Jun 18;41(12):2119-25. doi: 10.1016/s0735-1097(03)00463-7. J Am Coll Cardiol. 2003. PMID: 12821234 Free article. Clinical Trial.
Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop.
Newman JH, Fanburg BL, Archer SL, Badesch DB, Barst RJ, Garcia JG, Kao PN, Knowles JA, Loyd JE, McGoon MD, Morse JH, Nichols WC, Rabinovitch M, Rodman DM, Stevens T, Tuder RM, Voelkel NF, Gail DB; National Heart, Lung and Blood Institute/Office of Rare Diseases. Newman JH, et al. Among authors: badesch db. Circulation. 2004 Jun 22;109(24):2947-52. doi: 10.1161/01.CIR.0000132476.87231.6F. Circulation. 2004. PMID: 15210611 No abstract available.
Ambrisentan therapy for pulmonary arterial hypertension.
Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ. Galié N, et al. J Am Coll Cardiol. 2005 Aug 2;46(3):529-35. doi: 10.1016/j.jacc.2005.04.050. J Am Coll Cardiol. 2005. PMID: 16053970 Free article. Clinical Trial.
Autoimmunity and pulmonary hypertension: a perspective.
Nicolls MR, Taraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF. Nicolls MR, et al. Among authors: badesch db. Eur Respir J. 2005 Dec;26(6):1110-8. doi: 10.1183/09031936.05.00045705. Eur Respir J. 2005. PMID: 16319344 Free article. Review.
Temporal trends and drug exposures in pulmonary hypertension: an American experience.
Walker AM, Langleben D, Korelitz JJ, Rich S, Rubin LJ, Strom BL, Gonin R, Keast S, Badesch D, Barst RJ, Bourge RC, Channick R, Frost A, Gaine S, McGoon M, McLaughlin V, Murali S, Oudiz RJ, Robbins IM, Tapson V, Abenhaim L, Constantine G. Walker AM, et al. Am Heart J. 2006 Sep;152(3):521-6. doi: 10.1016/j.ahj.2006.02.020. Am Heart J. 2006. PMID: 16923424
173 results